Abstract
Background and Aims: Interleukin 6 [IL-6] or its receptor is currently a candidate for targeted biological therapy of inflammatory bowel disease [IBD]......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
